A Phase 1 interventional study of LY3484356 and Omeprazole in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant's involvement with the study will last approximately 27 days, not including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized (1:1) to 1 of 2 treatment sequences; LY3484356 administered as single doses orally with (fed) or without food (fasted) as below: Period 1: Single dose of 400 mg LY3484356 in the fasted state. Period 2: Single dose of 400 mg LY3484356 in the fed state. There was a washout period of 4 days between doses of LY3484356
Drug: LY3484356
Participants were randomized (1:1) to 1 of 2 treatment sequences; LY3484356 administered as single doses orally with (fed) or without food (fasted) as below: Period 1: Single dose of 400 mg LY3484356 in the fed state. Period 2: Single dose of 400 mg LY3484356 in the fasted state. There was a washout period of 4 days between doses of LY3484356.
Drug: LY3484356
Participants received single dose of LY3484356 and a single dose of omeprazole alone and in combination administered orally as below: Day 1: 400 mg LY3484356 alone Days 5 to 8: 40 mg omeprazole alone once daily Day 9: 400 mg LY3484356 + 40 mg omeprazole once There was a washout period of 8 days between doses of LY3484356.
Drug: LY3484356 · Drug: Omeprazole
Participants received single dose of LY3484356 and a single dose of Itraconazole alone and in combination administered orally as below: Day 1: 200 mg LY3484356 alone Days 5 to 9: 200 mg itraconazole alone (twice on Day 5 \[dose separated by approximately 12 hours\], then once daily on Days 6 through 9) Day 10: 200 mg LY3484356 + 200 mg itraconazole once (coadministered with the morning dose) Days 11 to 16: 200 mg itraconazole alone once daily. There was a washout period of 9 days between doses of LY3484356.
Drug: LY3484356 · Drug: Itraconazole
Participants received single dose of LY3484356 and a single dose of carbamazepine alone and in combination administered orally as below: Day 1: 400 mg LY3484356 alone Days 6 to 8: 100 mg carbamazepine BID alone Days 9 to 11: 200 mg carbamazepine BID alone Days 12 to 17: 300 mg carbamazepine BID alone Day 18: 300 mg carbamazepine BID + 400 mg LY3484356 (coadministered with morning dose) Days 19 to 22: 300 mg carbamazepine BID alone Day 23: 300 mg carbamazepine alone (morning dose only). There was a washout period of 17 days between doses of LY3484356.
Drug: LY3484356 · Drug: Carbamazepine
Participants received single dose of Carbamazepine and a single dose of midazolam alone and in combination administered orally as below: Day 1: 1.2 mg midazolam alone Days 2 to 4: 100 mg carbamazepine BID alone Days 5 to 7: 200 mg carbamazepine BID alone Days 8 to 10: 300 mg carbamazepine BID alone Day 11: 300 mg carbamazepine BID + 1.2 mg midazolam (coadministered with morning dose) Days 12 to 13: 300 mg carbamazepine BID alone Day 14: 300 mg carbamazepine BID + 1.2 mg midazolam (coadministered with morning dose).
Drug: Carbamazepine · Drug: Midazolam
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1)
PK: AUC\[0-∞\] of LY3484356
Time frame: Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours (h) postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose
PK: AUC[0-∞] of LY3484356 (Cohort 2)
PK: AUC\[0-∞\] of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: AUC[0-∞] of LY3484356 (Cohort 3)
PK: AUC\[0-∞\] of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: AUC[0-∞] of LY3484356 (Cohort 4)
AUC\[0-∞\] of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: Time of Maximum Observed Concentration (Tmax) of LY3484356 (Cohort 1)
PK: Tmax of LY3484356
Time frame: Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 h postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose
PK: Tmax of LY3484356 (Cohort 2)
PK: Tmax of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: Tmax of LY3484356 (Cohort 3)
PK: Tmax of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: Tmax of LY3484356 (Cohort 4)
Tmax of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: Maximum Observed Concentration (Cmax) of LY3484356 (Cohort 1)
Cmax of LY3484356
Time frame: Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 h postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose
PK: Cmax of LY3484356 (Cohort 2)
Cmax of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: Cmax of LY3484356 (Cohort 3)
Cmax of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
PK: Cmax of LY3484356 (Cohort 4)
Cmax of LY3484356
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
| Milestone | Cohort 1 Sequence 1: 400 mg LY3484356 Fasted/ 400 mg LY3484356 Fed | Cohort 1 Sequence 2: 400 mg LY3484356 Fed/ 400 mg LY3484356 Fasted | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 10 | 20 | 29 | 15 |
| Received at least one dose of study drug | 5 | 3 | 10 | 20 | 29 | 15 |
| Completed | 5 | 3 | 9 | 19 | 18 | 14 |
| Not completed | 0 | 0 | 1 | 1 | 11 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 10 | 1 |
| Milestone | Cohort 1 Sequence 1: 400 mg LY3484356 Fasted/ 400 mg LY3484356 Fed | Cohort 1 Sequence 2: 400 mg LY3484356 Fed/ 400 mg LY3484356 Fasted | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 5 | 3 | 0 | 0 | 0 | 0 |
| Completed | 5 | 3 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
PK: AUC\[0-∞\] of LY3484356
| nanogram*hour per milliliter (ng*hr/mL) | Cohort 1: 400 mg LY3484356 Fasted | Cohort 1: 400 mg LY3484356 Fed |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1) | 1810 ± 59 | 4350 ± 39 |
PK: AUC\[0-∞\] of LY3484356
| ng*hr/mL | Cohort 2: LY3484356 + Omeprazole |
|---|---|
| Day 1 | 2270 ± 93 |
| Day 9 | 1960 ± 46 |
PK: AUC\[0-∞\] of LY3484356
| ng*hr/mL | Cohort 3: LY3484356 + Itraconazole |
|---|---|
| Day 1 | 1430 ± 58 |
| Day 10 | 3120 ± 41 |
AUC\[0-∞\] of LY3484356
| ng*hr/mL | Cohort 4: LY3484356 + Carbamazepine |
|---|---|
| Day 1 | 1950 ± 67 |
| Day 18 | 1090 ± 32 |
PK: Tmax of LY3484356
| hours | Cohort 1: 400 mg LY3484356 Fasted | Cohort 1: 400 mg LY3484356 Fed |
|---|---|---|
| PK: Time of Maximum Observed Concentration (Tmax) of LY3484356 (Cohort 1) | 8.00 (3.00 to 35.80) | 3.02 (2.00 to 8.00) |
PK: Tmax of LY3484356
| hours | Cohort 2: LY3484356 + Omeprazole |
|---|---|
| Day 1 | 6.02 (1.00 to 10.00) |
| Day 9 | 6.00 (4.00 to 36.00) |
PK: Tmax of LY3484356
| hours | Cohort 3: LY3484356 + Itraconazole |
|---|---|
| Day 1 | 6.00 (2.00 to 36.00) |
| Day 10 | 6.00 (1.00 to 12.00) |
Tmax of LY3484356
| hours | Cohort 4: LY3484356 + Carbamazepine |
|---|---|
| Day 1 | 4.00 (2.00 to 36.00) |
| Day 18 | 3.87 (1.00 to 8.00) |
Cmax of LY3484356
| nanogram per millilitre (ng/mL) | Cohort 1: 400 mg LY3484356 Fasted | Cohort 1: 400 mg LY3484356 Fed |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3484356 (Cohort 1) | 37.2 ± 51 | 143 ± 28 |
Cmax of LY3484356
| ng/mL | Cohort 2: LY3484356 + Omeprazole |
|---|---|
| Day 1 | 49.1 ± 61 |
| Day 9 | 39.6 ± 47 |
Cmax of LY3484356
| ng/mL | Cohort 3: LY3484356 + Itraconazole |
|---|---|
| Day 1 | 30.3 ± 57 |
| Day 10 | 56.7 ± 47 |
Cmax of LY3484356
| ng/mL | Cohort 4: LY3484356 + Carbamazepine |
|---|---|
| Day 1 | 49.6 ± 76 |
| Day 18 | 33.3 ± 41 |
Collected over Cohort 1: up to 19 days, Cohort 2: up to 24 days, Cohort 3: up to 27 days, Cohort 4: up to 37 days, and Cohort 5: up to 25 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: 400 mg LY3484356 Fasted | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Cohort 1: 400 mg LY3484356 Fed | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Cohort 2: 400 mg LY3484356 (Day 1) | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Cohort 2: 40 mg Omeprazole (Days 5 to 8) | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Cohort 2: 400 mg LY3484356 + 40 mg Omeprazole (Day 9) | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Cohort 3: 200 mg LY3484356 (Day 1) | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Cohort 3: 200 mg Itraconazole (Days 5 to 9) | 0/20 (0%) | 0/20 (0%) | 8/20 (40%) |
| Cohort 3: 200 mg LY3484356 + 200 mg Itraconazole (Days 10 to 16) | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Cohort 4: 400 mg LY3484356 (Day 1) | 0/29 (0%) | 0/29 (0%) | 2/29 (6.9%) |
| Cohort 4: 100 mg Carbamazepine (Days 6 to 8) | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| Cohort 4: 200 mg Carbamazepine (Days 9 to 11) | 0/28 (0%) | 0/28 (0%) | 6/28 (21.4%) |
| Cohort 4: 300 mg Carbamazepine + 400 mg LY3484356 (Days 12 to 22) | 0/28 (0%) | 1/28 (3.6%) | 16/28 (57.1%) |
| Cohort 4: 300 mg Carbamazepine (Day 23) | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Cohort 5: 1.2 mg Midazolam (Day 1) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Cohort 5: 100 mg Carbamazepine (Days 2 to 4) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Cohort 5: 200 mg Carbamazepine (Days 5 to 7) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Cohort 5: 300 mg Carbamazepine (Days 8 to 10) | 0/15 (0%) | 0/15 (0%) | 2/15 (13.3%) |
| Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 11) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Cohort 5: 300 mg Carbamazepine (Days 12 to 13) | 0/15 (0%) | 0/15 (0%) | 2/15 (13.3%) |
| Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 14) | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Event | Cohort 1: 400 mg LY3484356 Fasted | Cohort 1: 400 mg LY3484356 Fed | Cohort 2: 400 mg LY3484356 (Day 1) | Cohort 2: 40 mg Omeprazole (Days 5 to 8) | Cohort 2: 400 mg LY3484356 + 40 mg Omeprazole (Day 9) | Cohort 3: 200 mg LY3484356 (Day 1) | Cohort 3: 200 mg Itraconazole (Days 5 to 9) | Cohort 3: 200 mg LY3484356 + 200 mg Itraconazole (Days 10 to 16) | Cohort 4: 400 mg LY3484356 (Day 1) | Cohort 4: 100 mg Carbamazepine (Days 6 to 8) | Cohort 4: 200 mg Carbamazepine (Days 9 to 11) | Cohort 4: 300 mg Carbamazepine + 400 mg LY3484356 (Days 12 to 22) | Cohort 4: 300 mg Carbamazepine (Day 23) | Cohort 5: 1.2 mg Midazolam (Day 1) | Cohort 5: 100 mg Carbamazepine (Days 2 to 4) | Cohort 5: 200 mg Carbamazepine (Days 5 to 7) | Cohort 5: 300 mg Carbamazepine (Days 8 to 10) | Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 11) | Cohort 5: 300 mg Carbamazepine (Days 12 to 13) | Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 14) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatitis eInfections and infestations | 0/8 | 0/8 | 0/10 | 0/10 | 0/9 | 0/20 | 0/20 | 0/20 | 0/29 | 0/28 | 0/28 | 1/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| Event | Cohort 1: 400 mg LY3484356 Fasted | Cohort 1: 400 mg LY3484356 Fed | Cohort 2: 400 mg LY3484356 (Day 1) | Cohort 2: 40 mg Omeprazole (Days 5 to 8) | Cohort 2: 400 mg LY3484356 + 40 mg Omeprazole (Day 9) | Cohort 3: 200 mg LY3484356 (Day 1) | Cohort 3: 200 mg Itraconazole (Days 5 to 9) | Cohort 3: 200 mg LY3484356 + 200 mg Itraconazole (Days 10 to 16) | Cohort 4: 400 mg LY3484356 (Day 1) | Cohort 4: 100 mg Carbamazepine (Days 6 to 8) | Cohort 4: 200 mg Carbamazepine (Days 9 to 11) | Cohort 4: 300 mg Carbamazepine + 400 mg LY3484356 (Days 12 to 22) | Cohort 4: 300 mg Carbamazepine (Day 23) | Cohort 5: 1.2 mg Midazolam (Day 1) | Cohort 5: 100 mg Carbamazepine (Days 2 to 4) | Cohort 5: 200 mg Carbamazepine (Days 5 to 7) | Cohort 5: 300 mg Carbamazepine (Days 8 to 10) | Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 11) | Cohort 5: 300 mg Carbamazepine (Days 12 to 13) | Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 14) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/8 | 0/8 | 0/10 | 0/10 | 0/9 | 1/20 | 0/20 | 0/20 | 0/29 | 0/28 | 2/28 | 9/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/8 | 1/10 | 1/10 | 0/9 | 1/20 | 6/20 | 0/20 | 0/29 | 0/28 | 0/28 | 0/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| HeadacheNervous system disorders | 0/8 | 0/8 | 0/10 | 1/10 | 0/9 | 2/20 | 1/20 | 0/20 | 0/29 | 0/28 | 1/28 | 7/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| Covid-19Infections and infestations | 0/8 | 0/8 | 0/10 | 0/10 | 0/9 | 0/20 | 0/20 | 0/20 | 0/29 | 0/28 | 0/28 | 2/28 | 3/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| NauseaGastrointestinal disorders | 0/8 | 0/8 | 0/10 | 0/10 | 0/9 | 0/20 | 0/20 | 1/20 | 0/29 | 0/28 | 0/28 | 4/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| SomnolenceNervous system disorders | 0/8 | 0/8 | 0/10 | 0/10 | 0/9 | 0/20 | 0/20 | 0/20 | 0/29 | 0/28 | 2/28 | 0/28 | 0/20 | 0/15 | 0/15 | 0/15 | 2/15 | 0/15 | 0/15 | 0/14 |
| Abdominal painGastrointestinal disorders | 1/8 | 0/8 | 0/10 | 1/10 | 0/9 | 0/20 | 1/20 | 0/20 | 1/29 | 0/28 | 0/28 | 0/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| ConstipationGastrointestinal disorders | 0/8 | 1/8 | 1/10 | 0/10 | 0/9 | 1/20 | 0/20 | 0/20 | 1/29 | 1/28 | 3/28 | 3/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 1/15 | 0/15 | 0/14 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/10 | 0/10 | 1/9 | 0/20 | 0/20 | 0/20 | 0/29 | 0/28 | 0/28 | 0/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
| Amylase increasedInvestigations | 0/8 | 0/8 | 0/10 | 1/10 | 0/9 | 0/20 | 0/20 | 0/20 | 0/29 | 0/28 | 0/28 | 0/28 | 0/20 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/15 | 0/14 |
All enrolled participants.
| Age, Continuous(years) | Cohort 1: Sequence 1/Sequence 2 | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam | Total |
|---|---|---|---|---|---|---|
| Mean | 51.8 ± 6.9 | 58.6 ± 6.9 | 52.5 ± 9.2 | 49.8 ± 10.1 | 46.4 ± 10.4 | 51.1 ± 9.8 |
| Sex: Female, Male(Participants) | Cohort 1: Sequence 1/Sequence 2 | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 10 | 20 | 29 | 3 | 70 |
| Male | 0 | 0 | 0 | 0 | 12 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Sequence 1/Sequence 2 | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 11 | 18 | 8 | 45 |
| Not Hispanic or Latino | 5 | 5 | 9 | 11 | 7 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Sequence 1/Sequence 2 | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 2 | 8 | 2 | 18 |
| White | 4 | 7 | 18 | 21 | 13 | 63 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Sequence 1/Sequence 2 | Cohort 2: LY3484356 + Omeprazole | Cohort 3: LY3484356 + Itraconazole | Cohort 4: LY3484356 + Carbamazepine | Cohort 5: Carbamazepine + Midazolam | Total |
|---|---|---|---|---|---|---|
| United States | 8 | 10 | 20 | 29 | 15 | 82 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Apr 2022, 11 months.
Results were first posted in Dec 2025, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Imlunestrant · Carbamazepine